In targeting HR-deficient ovarian cancers different strategies can be adopted, ranging from conventional chemotherapy (platinum analogues, pegylated liposomal Doxorubicin, Topotecan, Etoposide and Gemcitabine) to PARP and cell-cycle/DNA-damage checkpoint inhibitors [6,26,27]. This evidence concerns the gene PARP1 and ovarian carcinoma.